Top
Millennium Post

Manufacturers of 94 drugs should submit price details to controller by April 28: NPPA

Manufacturers of 94 drugs should submit price details to controller by April 28: NPPA
In its latest measure, the national drug price regulator has asked all drug manufactures as well as marketing companies to furnish the price to retailer (PTR) for enabling NPPA to take appropriate action for ceiling price fixations under provisions of DPCO, 2013. The PTR is the price at which the retailer purchases goods from stockists or distributors.

In an official memorandum, the apex drug price controller has asked all the concerned manufacturers of 94 drugs to submit the sought information latest by April 28. The drug majors have also been asked to share their Moving Annual Turnover (MAT) for the month of August 2015 to fix ceiling price of different formulations.

The drugs of which PTR has been sought by NPPA include Ritonavir that is used along with other medications to treat HIV/AIDS; Digoxin that is used to treat heart failure; Penicillamine that is used to treat rheumatoid arthritis, etc.

Prior to this order, the NPPA had fixed the prices of 70 drug formulation packs, including those used for treatment of bacterial infections, cancer, etc, which was not taken well by pharmaceutical industry. Objecting NPPA’s move, Indian Pharmaceutical Alliance (IPA) had filed a review petition with the Department of Pharmaceuticals (DoP) following a March 2 notification by the NPPA.

According to D G Shah, secretary-general of IPA that represents India’s 20 leading drug makers, the notification, which fixed or revised prices of 530 scheduled formulation packs as per the Wholesale Price Index (WPI) effective from April 1, had stated that the prices of formulations that were already lower than the ceiling price would have to be reduced by 2.71 per cent.

Last month, NPPA had fixed the ceiling price of as many as 103 drugs, including those used for treating HIV/AIDS, bacterial infections, tuberculosis, high blood pressure, epilepsy, Hepatitis C and diabetes. 


NPPA moves to control prices of 94 formulations mainly used for treatment of cardiovascular diseases, HIV/AIDS, anxiety, rheumatoid arthritis, etc

Regulator has asked all drug manufactures and marketing companies to furnish price to retailer for enabling NPPA to take appropriate action for ceiling price fixations under provisions of DPCO, 2013

Drugs of which PTR has been sought by NPPA include Ritonavir -- used along with other medications to treat HIV/AIDS; Digoxin – used to treat heart failure; Penicillamine – used to treat rheumatoid arthritis, etc

Next Story
Share it